收藏切换
Cost-utility analysis of eculizumab in the treatment of paroxysmal nocturnal hemoglobinuria
收藏切换
Zehua SONG1, 2, 3, Shixian LIU1, 2, 3, Shunping LI1, 2, 3, *, Lei DOU1, 2, 3, Hao CHEN1, 2, 3
World Clinical Drug | 2024, 45(9) : 991 - 1000
Less
收藏切换
World Clinical Drug | 2024, 45(9): 991-1000
• Pharmacy administration •
Cost-utility analysis of eculizumab in the treatment of paroxysmal nocturnal hemoglobinuria
Full
Zehua SONG1, 2, 3, Shixian LIU1, 2, 3, Shunping LI1, 2, 3, *, Lei DOU1, 2, 3, Hao CHEN1, 2, 3
Affiliations
  • 1.Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong Province, China
  • 2.NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, Shandong Province, China
  • 3.Center for Health Preference Research, Shandong University, Jinan 250012, Shandong Province, China
Published: 2024-09-10 doi: 10.13683/j.wph.2024.09.016
Outline
收藏切换
Objective

To evaluate the cost-utility of eculizumab versus supportive therapy in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Methods

From the perspective of whole Chinese society, a partitioned survival model was constructed to simulate the total cost, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) of patients over a lifetime (40 years) with a discount rate of 5%. One-way sensitivity analysis and probabilistic sensitivity analysis were used to verify the robustness of the model.

Results

The base-case results showed that compared with supportive therapy, patients who used eculizumab could obtaine 8.50 more QALYs and an incremental cost of 639 784 CNY, the ICER was 75 297 CNY/QALY, which was lower than the GDP per capita in 2023. The one-way sensitivity analysis showed that the annual spontaneous remission rate had the most significant impact on the final result. The probabilistic sensitivity analysis showed that the probability of cost-effective of eculizumab was 99.98% when the willingness-to-pay threshold was 3 times of GDP per capital.

Conclusion

From the perspective of the Chinese society, eculizumab was a cost-effective treatment regimen compared to supportive therapy in the treatment of PNH patients.

eculizumab  /  paroxysmal nocturnal hemoglobinuria  /  cost-utility analysis  /  partition survival model
宋泽华, 刘世贤, 李顺平, 窦蕾, 陈豪. 依库珠单抗治疗阵发性睡眠性血红蛋白尿症的成本-效用分析. 世界临床药物, 2024 , 45 (9) : 991 -1000 . DOI: 10.13683/j.wph.2024.09.016
Zehua SONG, Shixian LIU, Shunping LI, Lei DOU, Hao CHEN. Cost-utility analysis of eculizumab in the treatment of paroxysmal nocturnal hemoglobinuria[J]. World Clinical Drug, 2024 , 45 (9) : 991 -1000 . DOI: 10.13683/j.wph.2024.09.016
Year 2024 volume 45 Issue 9
9
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.09.016
  • Receive Date:2024-03-25
  • Online Date:2026-11-17
  • Published:2024-09-10
Article Data
Affiliations
History
  • Received:2024-03-25
Funding
Affiliations
    1.Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong Province, China
    2.NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, Shandong Province, China
    3.Center for Health Preference Research, Shandong University, Jinan 250012, Shandong Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.09.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT